深交所向内蒙古福瑞医疗科技股份有限公司及相关责任人发出监管函

Core Points - The company, Inner Mongolia Furu Medical Technology Co., Ltd., has received a regulatory letter from the Shenzhen Stock Exchange regarding several compliance issues [1][2][3][4] Group 1: Internal Control and Management Issues - The company lacks adequate internal control and risk management systems for its overseas subsidiaries, with no inspections or supervision conducted by internal departments [1] - The chairman and general manager, Wang Guanyi, along with the board secretary and acting CFO, Sun Xiuzhen, have not fulfilled their duties diligently, bearing primary responsibility for the company's violations [3] Group 2: Revenue Recognition Issues - The company has been found to have irregularities in revenue recognition, including premature revenue recognition of 2.4089 million yuan, 2.881 million yuan, 5.6703 million yuan, and 1.3417 million yuan for the years 2023 and 2024 [2] - The company improperly recognized full revenue for a drug sale with a return clause, which was later returned, leading to inaccuracies in the 2023 semi-annual report [2] - The company failed to reasonably estimate variable consideration in sales contracts, leading to full revenue recognition without appropriate adjustments for discounts and rebates [2] Group 3: Company Financials - For the year 2024, the company's revenue composition is entirely from the medical sector, with a 100% contribution from this segment [5] - As of the report date, the company's market capitalization stands at 18.4 billion yuan [6]